Half-dose photodynamic therapy for chronic central serous chorioretinopathy: Efficacy and safety outcomes in real world

- One of the few published evaluations of efficacy of half-dose PDT in chronic CSC.
- Good results under a personalized approach.
- Our work demonstrates the need of other add up treatments for a better final outcome

PurposeTo have an insight of the outcomes of half-dose photodynamic therapy (PDT) for patients with chronic central serous chorioretinopathy (CSC) in a real world population.Material and methodsThis is a retrospective consecutive case series, one-centre study, with a 12-month follow-up period.ResultsThe study took into account 15 eyes of 13 patients. All patients were male in gender and only 1 eye belonged to a non-caucasian. The sample mean age was 51,27 ± 11,66 (between 36 and 74 years); mean baseline best-corrected visual acuity (BCVA) was 0,40 ± 0,25 logMAR and central macular thickness (CMT) was 411,40 ± 88,44 μm. All patients had subretinal fluid (SRF) and retinal pigment epithelium (RPE) detachment involving the fovea. In a month time, BCVA and CMT had remarkable improvements with only one eye not gaining letters. At 6-month visit, 46,7% of the eyes were provided with additional treatment (intra-vitreal anti-VEGF or PDT). In the final visit no eye had worsened more than 5 letters and 53,3% had a BCVA improvement of at least 5 letters, with only 2 eyes remaining with RPE detachment and SRF. There was a steady regression in CMT throughout the follow-up; 93,3% had CMT under 300 μm and CMT mean was 249,93 ± 72,78 μm. There were no reported complications.ConclusionThese results support PDT as a valuable approach for therapeutic decisions on chronic CSC as well as the need of other add up treatments for a better final outcome. Further evaluations with longer follow-up's should be taken into consideration for safety issues.